10x Genomics Q2 Earnings Call Highlights

Impact · against what's priced in

TXG is seeing strong early demand for the Atera platform, which has already exceeded full-year shipment expectations and carries higher potential consumable pull-through. While instrument revenue is currently sagging during the product transition, the raised full-year revenue guidance suggests a positive trajectory.

TXG+0.50

No priced-in read yet

In context

Booked orders for Atera have already exceeded the 40-system full-year shipment target, and the platform's estimated annual consumable utilization of $1.5M–$3M is double that of Xenium.

Read from the article alone

• biotech▲53%
• earnings▲44%
• guidance▲33%
• TXG
• genomics
• healthcare tech
• life sciences